Effect of metoclopramide on nosocomial pneumonia in patients with nasogastric feeding in the intensive care unit

M. Nassaji,1 R. Ghorbani,2 M. Frazeshfard3 and F. Mesbahian4

ABSTRACT This study in the Islamic Republic of Iran aimed to determine whether metoclopramide can prevent nosocomial pneumonia in the intensive care unit (ICU). Of 220 patients admitted to the surgical ICU who had a nasogastric tube for more than 24 hours, 68 case patients received oral metoclopramide (10 mg every 8 hours) and 152 control patients did not. Similar proportions of cases and controls developed nosocomial pneumonia (33.8% versus 33.6%). Endotracheal intubation was a risk factor for nosocomial pneumonia (odds ratio 7.70). There were no significant differences between groups in mortality rate or time of onset of nosocomial pneumonia. Metoclopramide appears to have no effect on the development of nosocomial pneumonia with nasogastric feeding.

1Department of Infectious Diseases, Fatemieh Hospital; 2Department of Social Medicine; 3Department of Anaesthesiology, Amir Hospital; 4Emergency Ward, Semnan University of Medical Sciences, Semnan, Islamic Republic of Iran (Correspondence to M. Nassaji: hnassaji@yahoo.com).
Received: 25/12/07; accepted: 05/05/08
**Introduction**

Nosocomial pneumonia (NP) is an inflammation of the lung parenchyma that develops 48–72 hours after admission to hospital due to infectious agents not incubating at the time of admission [1]. Despite an increased understanding of its pathogenesis and advances in diagnosis and treatment, the risk, cost, morbidity and mortality associated with NP remain unacceptably high. It is one of the leading causes of extended hospital stays and death from hospital-acquired infections [2].

Nasogastric tube feeding has been shown to be a risk factor for development of NP in hospital, possibly due to aspiration of pathogenic microorganisms that have colonized the gastrointestinal tract (GIT) and oropharynx [3,4]. The mechanism is believed to be a modification to gastric pH that causes bacterial overgrowth in the stomach together with an increase in gastric volume during nasogastric tube feeding that facilitates reflux of gastric contents into the pharynx leading to aspiration of gastric contents, tracheal colonization and eventually pneumonia in some patients [5–7]. The physical presence of the nasogastric tube across the lower oesophageal sphincter may impair contraction, prevent sphincter closure and promote reflux of gastric contents [8,9].

Several drugs have been used to prevent oesophageal reflux of gastric contents in patients suffering from gastric reflux. Metoclopramide is a prokinetic agent that results in coordinated contraction and enhances transit in the GIT. Its effects are confined largely to the upper GIT. It increases lower oesophageal sphincter tone and stimulates antral and small intestine contraction, but has no effect on oesophageal peristalsis [10]. This makes it a promising agent for reducing reflux and the risk of NP in the intensive care unit (ICU).

Because there are a few studies that have evaluated the role of antireflux drugs in the prevention of NP, we designed this study to evaluate the possible effect of metoclopramide on ICU patients receiving nasogastric feeding.

**Methods**

In this double-blind clinical trial, all adult patients admitted to a 10-bed surgical ICU in Semnan, Islamic Republic of Iran, were eligible for enrolment if they required placement of a nasogastric tube for more than 24 hours. All patients were given standard ICU care with no special measures to reduce the incidence of NP. Patients who already had pneumonia, had received a nasogastric tube before ICU admission or who were discharged or died within 48 hours after admission were excluded.

The study was approved by the Semnan University of Medical Sciences ethics committee. Informed written consent was obtained from all patients (where possible) or their next-of-kin in the case of unconscious patients.

Patients were randomized into 2 groups with the first patient entering the ICU being assigned to the case group and the following 2 patients to the control group and so on. One group (case patients) received metoclopramide (10 mg every 8 hours) through the nasogastric tube. The other group (control patients) did not receive metoclopramide. We recorded the baseline characteristics of the patients, including age, sex, primary diagnosis, tracheal intubation and outcome (dead or alive). Metoclopramide was continued daily for a maximum of 5 days unless the patient developed NP or died.

Baseline complete blood count and chest X-ray were done. Patients were examined daily by the same infectious diseases specialist for development of NP. Pneumonia was defined as the presence of all of the following criteria: axillary temperature > 37.5 °C, leukocytosis (white blood cell count > 11 000 cells/L), increase in tracheal secretions (> 0.4 cm/h) and new infiltrate on the chest radiograph or progression of an existing infiltrate. Patients were followed until discharge from the ICU or death. NP that developed before 5 days was defined as early-onset NP and ≥ 5 days as late-onset NP.

We analysed the data using chi-squared, Fisher exact, unpaired Student t-test and logistic regression using SPSS software, version 11.5.

**Results**

A total of 220 patients were included over a 16-month period: 68 received metoclopramide. The characteristics of the patients are shown in Table 1. The mean age of cases was 41.5 (standard deviation 23.9) years and of controls was 46.4 (SD 24.8) years. The most common underlying problem in both groups was neurosurgical problems. The mean time of hospitalization in cases was 9.0 days and in the controls was 10.5 days.

Almost the same proportion of cases (23/68, 33.8%) and controls (51/152, 33.6%) developed pneumonia (P = 0.969). Other findings are shown in Table 2. There were no significant differences between the case and control groups in the proportion of patients who died (27.9% versus 38.8% respectively) (P = 0.119). Among 143 patients with tracheal intubation, similar proportions of cases (18/37, 48.6%) and controls (49/106, 46.2%) developed NP. Early-onset NP developed in 23 cases (33.8%) and 39 controls (25.8%) (P = 0.014).

To adjust for the effect of metoclopramide in the development of NP, stepwise logistic regression was used. The only variables remaining significant after regression analysis were neurosurgical problems and intubation (Table 3). Patients having neurosurgery had a greater risk of developing NP compared with patients with laparotomy or other procedures (odds ratio (OR) 2.88; 95%
The risk of aspiration of gastric contents into the lower airways is believed to be related to the presence of gastroesophageal reflux. In studies evaluating the efficacy of metoclopramide on prevention of acid aspiration it has been shown that it decreases the volume of gastric contents to less than 20–25 mL in 62%–87% of patients, without any significant effect on gastric pH. It also increases the lower oesophageal sphincter pressure [11–14]. Several studies have demonstrated that nasogastric tube feeding increases gastric volume and pressure and bacterial contamination with Gram-negative bacilli. It also disrupts the oesophagogastric barrier, promoting transfer of gastric microorganisms into the pharynx and trachea, and is associated with a several-fold increase in the risk of developing NP [4,15,16]. We hypothesized that metoclopramide, by reducing the reflux of gastric contents into the oesophagus and nasopharynx, may also help to reduce the frequency of NP.

Gastroesophageal reflux is a very common phenomenon in critically ill patients and is probably related to the presence of the nasogastric tube and mechanical ventilation. Manchikanti et al. concluded that the addition of metoclopramide to the preanaesthetic preparation of patients would be effective for prophylaxis of aspiration pneumonia [16]. Our findings showed that treatment with metoclopramide in critically ill patients had no effect on the proportion of patients who developed NP or on the mortality rate. In agreement with our finding, Yavagal et al. concluded that metoclopramide did not decrease the frequency of developing NP or the mortality rate [17].

Previous studies have demonstrated that the risk of NP associated with nasogastric tube feeding was highest in patients receiving mechanical ventilation. Positive gastric pressure during ventilation may increase oesophageal reflux [15,18]. In our study the risk of NP in patients with tracheal intubation was 7.70 times greater than in those without intubation. We found that metoclopramide had no preventive effect in these subgroups.

There was no significant difference between the case and control groups in the timing of onset of NP, comparing late (≥ 5 days) and early-onset NP (< 5 days). In contrast, Yavagal et al. concluded that metoclopramide delayed the development of NP by an average of 1.5 days [17]. Most studies that have shown a preventive effect of metoclopramide were in patients having elective surgery, i.e. those who were not critically ill [11,12,16]. There are many problems...
in critically ill patients that may interfere with the preventive effect of this drug: decreased GIT perfusion impairs absorption; the autonomic effect of stress or pain impairs GIT motility; and concurrent use of other drugs (i.e. opioids, dopamine) impairs motility. We used the oral form of the drug, which may explain its lack of effectiveness.

Apart from regurgitation of gastric contents, another postulated mechanism for the development of NP is migration of bacteria along the tube from the stomach to the upper airways [4]. Drugs that reduce gastroesophageal reflux will not have any effect on this mechanism.

In conclusion, oral metoclopramide in the dose used in this study (10 mg every 8 hours) did not reduce the risk of developing NP in ICU patients with nasogastric feeding.

Because of the small numbers involved, the odds ratios were quite wide, especially for intubation, and the study therefore did not have sufficient power. We did not perform gastric motility studies, oesophageal pH manometry or measurement of metoclopramide levels in plasma and therefore we cannot conclude that metoclopramide failed to prevent gastroesophageal reflux. Another limitation of the study was that more cases than control patients had neurosurgical problems and increased intracranial pressure is associated with impaired gastric emptying. Studies that monitor the metoclopramide level in plasma, that use a higher dose or the injection form of metoclopramide and that have a larger sample size are recommended.

### References